Abstract: Cutaneous eruptions are among the most common immune-related adverse events (irAEs) associated with antiprogrammed cell death protein 1/programmed cell death ligand 1 therapy, and are often clinically and histologically characterized as lichenoid. Nonlichenoid patterns may also occur and are likely to be encountered by surgical pathologists, given the increasing clinical use of these agents. The purpose of this study is to describe the histopathologic features of nonlichenoid cutaneous irAEs from patients receiving anti-programmed cell death protein 1/programmed cell death ligand 1 therapies for a variety of underlying advanced malignancies. Sixteen patients with 17 biopsied eruptions were included from 2 academic institutions with extensive experience administering and monitoring responses to immune checkpoint blockade as well as treating the potential side effects. Eruptions occurred a median of 10 days (range, 1 d to 11.4 mo) after treatment initiation. Nearly half of specimens demonstrated either a psoriasiform/spongiotic or an urticarial-type reaction pattern on histologic review. Patterns consistent with Grover disease, bullous pemphigoid, and granulomatous dermatitis were also observed. Nearly two-thirds of patients required systemic corticosteroids for treatment of the cutaneous irAE, and 19% of patients discontinued immunotherapy due to their skin eruptions. 75% of patients showed an objective antitumor response. The diverse array of nonlichenoid cutaneous irAE presented here should reflect and inform the scope of histologic patterns encountered by the practicing surgical pathologist. Such eruptions are seen in patients with a variety of underlying tumor types, many of whom ultimately demonstrate a favorable response to immune checkpoint blockade.
This unbridled immune response can result in durable clinic benefit, but in some cases may trigger immunerelated adverse events (irAEs) in multiple organ systems. Cutaneous irAEs develop in approximately 15% to 20% of patients receiving anti-PD-1/PD-L1 1,2 and have been reported to occur relatively early in the course of treatment. 3 Notably, the incidence of cutaneous irAEs seems to vary by tumor type: approximately 40% to 46% of patients with melanoma 4 and 41% of patients with renal cell carcinoma 5 will develop cutaneous irAEs associated with anti-PD-1 therapy, as compared with 17% in patients with non-small cell lung cancer (NSCLC) 4 and 18% of patients with squamous-cell carcinoma of the head and neck. 6 Patients present commonly with nonspecific morbilliform eruptions, but alternate clinical presentations reported with anti-PD-1/PD-L1 include psoriasis, [7] [8] [9] [10] [11] bullous pemphigoid (BP), [12] [13] [14] [15] [16] sarcoidosis, [17] [18] [19] and Stevens Johnson syndrome/toxic epidermal necrolysis. 20 For a detailed, comprehensive review of the broad array of presentations published to date, see Curry et al. 21 Histologic presentations may also vary, with the lichenoid (or interface) pattern being the most commonly recognized. [22] [23] [24] [25] [26] [27] [28] [29] Immunohistochemical analysis of anti-PD-1-induced lichenoid dermatitis shows similarity to idiopathic lichen planus 24 and suggests a T cell-mediated process, 23 which is consistent with the recognized mechanism of action for these agents.
While immune-related lichenoid reactions are frequently seen in patients who are biopsied for cutaneous irAEs, other histologic patterns may be encountered in clinical practice. The purpose of this study was thus to comprehensively describe the clinicopathologic characteristics of the nonlichenoid dermatologic toxicities associated with these agents. Here, we define the spectrum of reaction patterns seen at 2 major academic institutions that are leading the investigations into usage of these agents in a wide variety of tumor types. We assessed the time to onset of the biopsy-confirmed eruptions, treatment of the eruptions, the association of nonlichenoid cutaneous irAE with irAE in other organ systems, and correlation of the irAE with response to treatment. Many of the observed histologic patterns have been published 8LFT elevations attributed to combination of patient's underlying Gilbert disease, alcohol intake, and anti-PD-1 regimen. zOn the basis of limited description, no clinical photo available. #Pruritic rash approximately 3 months before appearance of bullae. **Some cases (often those with the urticarial-type reaction pattern) showed small foci of spongiosis or vacuolar interface reaction. wwPatient had an initial biopsy done also demonstrating bullous pemphigoid, 161 days after first infusion and located on back; treated with clobetasol spray, dose delayed but was resumed.
zzPatient initially presented with diffuse macular eruption 7 days after first dose of checkpoint blocking agent, which was controlled with a prednisone taper; patient continued on low-dose prednisone and was taken off protocol approximately 1 year later, continuing with low-dose steroids for another 9 months; at this point prednisone was tapered further and cutaneous eruption was reported to recur approximately after 1 month on lower dose, with flaring of longstanding psoriasiform plaque on leg; biopsies were performed 4 days later.
yyThought to be drug-related irAE superimposed on chronic psoriasiform eruption. CR indicates complete response; CRC, colorectal adenocarcinoma; HNSCC, head and neck squamous cell carcinoma; F, female; LFT, liver function test; M, male; MM, metastatic melanoma; MSI-H, microsatellite unstable; PR, partial response; RCC, renal cell carcinoma; SD, stable disease.
singularly or in conjunction with cohorts that also included lichenoid eruptions, however, the associated clinical correlates specific to nonlichenoid patterns were either not captured or were not collected and reported in a standardized manner.
MATERIALS AND METHODS
Institutional Review Board approval for the study was obtained from both Johns Hopkins Hospital (JHH) and Memorial Sloan Kettering Cancer Center (MSKCC). JHH patients who developed a cutaneous eruption following treatment with anti-PD-1/PD-L1 monotherapy or combination therapy with anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) for any advanced malignancy were eligible for inclusion. Patients were referred by their treating oncologist and/or dermatologist. MSKCC patients had underlying NSCLC and were referred to dermatology for eruptions while receiving anti-PD-1/PD-L1 monotherapy or in combination with anti-CTLA-4. Only patients with biopsy specimens available for review were included. Histologic patterns were assessed by 2 dermatopathologists (J.M.T. and J.D.C.) who were blinded to treatment outcome. Clinical information was gathered retrospectively from the medical record (Table 1 
RESULTS
From 2010 to 2016, 18 patients at JHH were biopsied for treatment-associated cutaneous eruptions. One patient had 2 different skin morphologies that were each biopsied. Among these 19 specimens, 9 (47%) were histopathologically characterized as lichenoid and excluded (Supplemental Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/PAS/ A520). Seven additional nonlichenoid skin specimens from 2012 to 2015 were obtained from unique patients treated at MSKCC. Patient characteristics and treatment course for the final cohort of 16 patients with 17 nonlichenoid eruptions are described in Table 1 .
The reported time to onset ranged from 1 day to 11.4 months (median, 10 d; mean, 66 d) after the first Notably, 3 of the 5 patients with eruptions demonstrating psoriasiform features reported a prior history of lesions in keeping with possible psoriasis, but did not carry a formal diagnosis. Focal acantholytic dermatosis, that is, Grover disease-like eruptions, were observed in 3 patients, all of whom also reported an associated pruritis. The age/sex of the patients, distribution of lesions, and temporal relationship to treatment initiation support that these were drug-related and not incidental, concurrent idiopathic presentations of Grover disease. 30 Two patients, both with underlying NSCLC treated with combined anti-PD-1 and anti-CTLA-4, demonstrated a granulomatous dermatitis on histology; neither had a prior history of sarcoidosis. Three patients presented with direct immunofluorescence-confirmed BP, 2 of whom halted anti-PD-1/PD-L1 due to the eruption; the other patient was dose-delayed due to ongoing corticosteroid treatment for his BP, but achieved a complete tumor response during this time and did not restart anti-PD-1 therapy. Three patients required cessation of therapy due to the cutaneous irAE, 10 patients (63%) received systemic corticosteroids to control the eruption, and 9 patients (56%) had irAEs affecting other organ systems ( Table 1) . The majority of patients were able to continue treatment and antitumor responses were favorable, with 75% (12/16) of patients demonstrating a partial or complete response and one additional patient demonstrating stable disease for greater than 6 months, with a median follow-up time of 30 months.
DISCUSSION
Immune checkpoint blockade agents are frequently associated with dermatologic irAEs 31 demonstrating variable clinical and histologic morphologies (Table 2 for biopsy-confirmed nonlichenoid patterns, and Curry et al 21 for a comprehensive literature review of studies reporting cutaneous irAE). Previous reports of cutaneous toxicities associated with checkpoint blockers have reported lichenoid patterns in 54% to 94% of biopsied cases (Supplemental Table 2 , Supplemental Digital Content 1, http://links.lww.com/PAS/A520). We found that 47% of biopsied eruptions encountered during routine service by the general surgical pathologists and dermatopathologists showed a lichenoid histology. Herein, we report the other histologic patterns observed, which accounted for the other half of biopsies received and includes a spectrum of nonlichenoid patterns. For the nonlichenoid eruptions, the median time to onset was 10 days, but a subset of patients experienced a notably delayed onset. Among these were the patients with BP who presented between 2.8 and 11.4 months after starting treatment. This finding of delayed immunobullous eruptions is consistent with previous reports. 12, 15 Interestingly, our cohort also included patients with vitiligo, granulomatous dermatitis, and an urticarial-type reaction, which also occurred over 2 months after treatment initiation. Ten of 16 (63%) patients required systemic steroids (again including a number of patients without BP), which is a higher proportion than reported for biopsied lichenoid eruptions. 24, 25 Over half of patients experienced irAEs in other organ systems, including arthritis/arthralgia in 4 patients, endocrinopathies in 4 patients, and 2 patients each affected by colitis, pneumonitis, and LFT elevations. Collectively, the patterns of delayed onset, the need for oral corticosteroids in the majority of cases, and the systemic autoimmune effects (Table 1 ) observed in patients with nonlichenoid eruptions suggest a potential mechanism of systemic inflammation stimulated by immune checkpoint blockade that may persist long after the initial activation event and possibly mediating both sustained antitumor effect and both cutaneous and noncutaneous irAEs. 12 The occurrence of cutaneous eruptions from checkpoint agents have been associated with overall survival in patients with melanoma receiving anti-PD-1 3 and improved antitumor responses in NSCLC. 35 For lichenoid eruptions in particular, response rates as high as 69% have been reported. 25 The 75% objective response rate described here thus confirms this previous finding and extends it to include the nonlichenoid pattern of irAEs. Our findings also indicate that the association between nonlichenoid irAEs and therapeutic clinical benefit includes patients with tumor types beyond melanoma and NSCLC.
Several clinical features favored the anti-PD-1/PD-L1 immunotherapy as the causative agent in these patients. In some cases, the cutaneous eruption was temporally very proximal to anti-PD-1 treatment initiation (patients 1, 5, 8, 10, 12, 14, 15) ; additionally, the dermatologic toxicity was seen to improve with anti-PD-1/PD-L1 treatment cessation and/or reappeared or worsened after each dose (patients 1, 4, 5, 11). Some patients had atypical eruptions that diverged from the classical clinical presentations. For example, BP is unusual in a 40-yearold patient such as patient 4 (BP typically affects those 70 years of age or older). 36 In addition, the blisters on this patient's skin improved but were persistent up to 4 months after discontinuation of the anti-PD-1 agent, which is consistent with a previous study of immunobullous eruptions associated with anti-PD-1 therapy and in contrast to other types of drug-related BP. 12 A definitive understanding of the immune subsets and target antigens underlying irAEs, and the factors that 23, 24 Th1/Th17 cells, 7 and regulatory T cell depletion. 37 By contrast, the development of BP may be due to antibody recognition of a common antigen displayed at both the basement membrane of the skin and on underlying tumor cells. 12 The longer time to onset in these patients suggests that B cell-mediated antibody generation is prolonged compared with a T cell-mediated response. A distinct mechanism of action is suggested by the appearance of Grover disease-like eruptions, that is, a disorder of keratinocyte proliferation due to paradoxical activation of the MAP kinase pathway. 38 The variety of histologic patterns presented in our cohort underscores the potential complexity of the involved immune response, which may comprise both diverse T cell populations and antibody-mediated mechanisms of action as well as alternate signaling pathways.
In conclusion, the diverse clinical and histologic presentations and often delayed onset of irAEs in patients receiving anti-PD-1/PD-L1 checkpoint blockade highlight the importance of clinicopathologic correlation in attributing these varied histologic patterns to the use of checkpoint agents, as many of these nonlichenoid patterns may mimic their idiopathic counterparts. Surgical pathologists will undoubtedly receive an increasing number of biopsies from sites of irAEs as these immunoactive agents become standard of care in an increasing number of tumor types. In describing the diverse array of histologic patterns encountered at two academic institutions, we approach the prevalence of patterns that may be encountered in practice. Further study is warranted to more directly query the immune-mediated mechanisms that underlie diverse irAEs in patients undergoing treatment with immune checkpoint blockade.
